All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-01-10T13:40:11.000Z

JBI-802 granted orphan drug designation by the FDA

Jan 10, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new development in the treatment of AML.

Bookmark this article

On January 5, 2023, JBI-802, an oral, potent, selective dual inhibitor of two epigenetic targets of the transcriptional regulator CoREST complex, LSD1 and HDAC6, was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with acute myeloid leukemia.1

This designation is based on several relevant preclinical models, including erythroid leukemia, where JBI-802 demonstrated synergistic antitumor activity and a favorable safety profile.1

JBI-802 also received orphan drug designation for the treatment of small cell lung cancer.1 The first-in-human trial evaluating JBI-802 in multiple neuroendocrine tumors is ongoing, with plans to expand into hematologic cancers, including acute myeloid leukemia, essential thrombocythemia, and other myeloproliferative cancers.1

  1. Jubilant Therapeutics. Jubilant Therapeutics Inc. receives orphan drug designation for JBI-802 for acute myeloid leukemia (AML) and small cell lung cancer (SCLC). https://www.jubilanttx.com/pressreleasedetails.aspx?mpgid=1473&pgid=1475&pressid=489. Published Jan 5, 2023. Accessed Jan 10, 2023.

More about...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox